The next-generation checkpoint pipeline grows behind Opdualag

It’s been a long road to the market for next-generation checkpoint inhibitors. BMS’s Opdualag may be the first to cross the finish line, but there’s a deep and growing pipeline of candidates behind. 

On Friday, FDA approved an NDA for a fixed dose combination of relatlimab, an anti-LAG3 mAb from Bristol Myers Squibb Co. (NYSE:BMY), and the pharma’s marketed PD-1 inhibitor Opdivo nivolumab. ...